Dr. Daniela Fliegner is currently the Global Medical Director for Eliquis at Pfizer, a position held since 2022. Previously, from 2017 to 2020, they served as a Senior Medical & Scientific Advisor in Internal Medicine and led a team of Medical Affairs Scientists at Pfizer. Dr. Fliegner has also held significant roles at Bayer, including Laboratory Head in Heart and Lung Diseases and a shared postdoctoral researcher position focusing on sex-specific mechanisms in heart failure. Their academic journey includes a PhD at Charité Berlin, where they investigated sex-specific differences in cardiac metabolism. Additionally, Dr. Fliegner completed studies in communication management at Deutsche Presseakademie.
This person is not in the org chart
This person is not in any teams
This person is not in any offices